Vincent Mark D. 4

What Happened

• Mark D. Vincent, a former director of Aptose Biosciences (APTO), reported multiple dispositions in June 2026. He sold 14 shares on 2026-06-13 at US$1.72 ($24) and disposed of a combined ~522,333 additional shares on 2026-06-30 reported as derivative dispositions (multiple line items). Although many 6/30 entries show $0.00 (derivative reporting), the filing notes these were disposed pursuant to a board, shareholder and court-approved business arrangement under which a Hammi Pharmaceuticals subsidiary acquired all outstanding Aptose shares at C$2.41 per share (converted at C$1.40 = US$1.00), implying total consideration of roughly US$898,437 for the full block (all dates combined ≈ US$898,437).

Key Details

• Transaction dates & prices:
  • 2026-06-13: 14 shares at US$1.72 (reported value US$24).
  • 2026-06-30: multiple derivative dispositions totaling ~522,333 shares; transaction price was C$2.41/share (F1), converted at C$1.40 = US$1.72/share (F2) though reported as $0.00 for derivative entries.
• Shares disposed in total: ~522,347 (14 + ~522,333).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes of note:
  • F1: Dispositions pursuant to a court-approved business arrangement; Hammi subsidiary acquired outstanding shares at C$2.41/share.
  • F2: Canadian-to-US conversion used C$1.40 = US$1.00.
  • F3 & remark: Some disposals involved options/derivatives with stated vesting schedules and subject to prior reverse-split adjustments.
• Timeliness: Report filed 2026-07-01 for transactions through 2026-06-30 (appears timely).

Context

• Many entries are listed as derivative dispositions — the filing indicates these were surrendered/converted as part of the acquisition rather than open-market sales. For retail investors, transactions tied to a take-private or acquisition process reflect the deal consideration rather than an independent insider sentiment signal. Options-related footnotes note vesting schedules and reverse-split adjustments; these are administrative details of the instruments involved, not separate market trades.